PubMed Health⌕ Search

Biomedical subjects

M Garty

Publications and source records attributed to M Garty.

69 records · Page 4Linked to original sources
PubMed1984

Probucol with colestipol in the treatment of hypercholesterolemia.

The effects of therapy with 1 g of probucol and 20 g of colestipol were compared with those of the drugs used singly on 47 patients with hypercholesterolemia in a double-blind, double-placebo, diet-controlled, crossover trial that lasted 18 months. The probucol and colestipol combination, but neither drug alone, reduced mean serum low-density-lipoprotein (LDL)-cholesterol levels from 242 +/- 51 (SE) mg/dL during the diet and placebo phase to 171 +/- 41 mg/dL. Probucol significantly lowered high-density-lipoprotein (HDL)-cholesterol levels and increased LDL:HDL-cholesterol ratios. Combination therapy did not change LDL:HDL cholesterol ratios. Probucol alone or in combination reduced very-low-density-lipoprotein cholesterol levels, despite concomitant elevations of serum triglyceride levels caused by colestipol in the combination protocol. Gastrointestinal side effects of single drugs were abolished when drugs were used in combination. Compared with the values in the diet-placebo phase, LDL-cholesterol levels were reduced by more than 20% in 81% of patients, by more than 30% in 49%, and by more than 40% in 17%. This drug combination proved to be safer and have greater hypocholesterolemic effects in more patients than other marketed drug treatments.

Adult↗
PubMed1981

Digitoxin elimination reduced during quinidine therapy.

Elevated serum digoxin concentrations and clinical toxicity have been reported in patients receiving quinidine. The present study was undertaken to ascertain whether a similar interaction occurs between quinidine and another cardiac glycoside, digitoxin, and if so to evaluate the pharmacokinetic basis in five healthy volunteers. In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052). No change was observed in the apparent volume of distribution or in the volume of the central compartment for digitoxin. The data suggest that the mechanism for this interaction is a reduction in elimination and not displacement of digitoxin from tissue binding sites.

Adult↗
PubMed1980

Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.

In a randomized crossover study, five normal subjects were given 250-mg capsules of tetracycline at weekly intervals with cimetidine 300 mg. sodium bicarbonate 2 gm in water, magnesium-aluminum hydroxide gel 30 ml, or water alone. Gastric pH was monitored by radiotelemetry. Antibiotic bioavailability as measured by area under the serum level-time curve, peak serum level, and urinary elimination was not affected by cimetidine or sodium bicarbonate. Magnesium-aluminum hydroxide gel reduced bioavailability by 90%. The data show that gastric pH does not affect absorption of oral tetracycline and that cimetidine can be used in place of antacids to control gastric acid in patients using tetracycline.

Adult↗
PubMed1980

Effect of cimetidine on absorption of oral tetracycline in mice.

Gastric administration of cimetidine, 5 mg/kg, and magnesium aluminum hydroxide gel (Maalox), 1 ml/kg, were equally effective raising the gastric pH of mice from 2.5 to 5.0. The antacid depressed by 75% gastrointestinal absorption of tetracycline given by gastric tube at 25 mg/kg. Antibiotic bioavailability was measured by area under the plasma level-time curve, peak plasma level and urinary elimination. Cimetidine did not affect tetracycline absorption as reflected by any of these three parameters. If confirmed with the solid dosage form in man, the present study suggests that unlike magnesium aluminum hydroxide gel, cimetidine may be used as an effective means of reducing gastric acid in patients who take tetracycline.

Administration, Oral↗
PubMedDate not supplied

Immediate immunosuppression caused by acute HIV-1 infection: a fulminant multisystemic disease 2 days post infection.

A healthy 19-year-old woman had vaginal intercourse on a single occasion with an HIV-1 positive male from Gambia. Two days later she developed an acute HIV infection presenting as a fulminant multisystem disease that lasted for 35 hospital days and included: immediate immunosuppression with extreme CD4+ lymphocytopenia and combined with CD8+ lymphocytosis, neutropenia and hypogammaglobulinemia; intermittent spiking fever; pneumonitis; hepatitis; changing skin rashes; peripheral neuropathy with myopathy, and panencephalitis. P24 antigen was detected by Western blot on day 23 and seroconversion was detected by ELISA on day 25. Cultured lymphocytes from peripheral blood and cerebrospinal fluid grew HIV-1.

Adult↗